Generex Biotechnology Corporation
GNBTQ
OTC PK
| 04/30/2021 | 01/31/2021 | 10/31/2020 | 07/31/2020 | 04/30/2020 | |
|---|---|---|---|---|---|
| Net Income | 263.91% | -248.51% | -17.59% | -143.91% | 45.45% |
| Total Depreciation and Amortization | 22.61% | 22.56% | 25.25% | 360.74% | 32.89% |
| Total Amortization of Deferred Charges | -24.33% | -81.32% | -91.58% | -68.90% | -25.57% |
| Total Other Non-Cash Items | -1,504.23% | 863.63% | -202.31% | 1,230.22% | 274.15% |
| Change in Net Operating Assets | 163.04% | 407.41% | 453.45% | 106.55% | -45.18% |
| Cash from Operations | 166.14% | 64.69% | 27.57% | 58.16% | 78.67% |
| Capital Expenditure | -- | -- | -- | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Issued | 101.10% | -- | -- | -61.14% | -57.62% |
| Total Debt Repaid | -- | -- | 93.59% | 100.00% | -100.00% |
| Issuance of Common Stock | -- | 790.98% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -50.73% | -70.44% | 5.63% | -35.63% | -59.25% |
| Foreign Exchange rate Adjustments | -- | 633.33% | -633.33% | -13.33% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 631.03% | 12.43% | 238.34% | 63.84% | 115.28% |
